In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

Zach began writing for CNET in November, 2021 after writing for a broadcast news station in his hometown, Cincinnati, for five years. You can usually find him reading ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) stock is surging on Wednesday, without any news to justify the movement. Session volume stands at 69.3 million versus the average volume of 26.9 million, ...

Kara Alaimo is a professor of communication at Fairleigh Dickinson University. Her book “Over the Influence: Why Social Media Is Toxic for Women and Girls — And How We Can Take It Back” was published ...

Pull requests help you collaborate on code with other people. As pull requests are created, they’ll appear here in a searchable and filterable list. To get started, you should create a pull request.

With close to a decade of writing and editing experience, Maisha specializes in service journalism and has produced work in the lifestyle, financial services, real estate, and culture spaces. She uses ...

Palantir's stock is up nearly 10 % month-to-date and has gone even higher year-to-date, as bullish sentiment surges ahead of its second quarter earnings. Tempus AI shares, currently at about $64, have ...

BOSTON--(BUSINESS WIRE)--Factorial Inc. (Factorial), a leader in solid-state battery technology, today announced the launch of Gammatron™, a proprietary AI-driven simulation platform designed to ...

Shares of Recursion Pharmaceuticals (NASDAQ:RXRX) traded higher in the premarket on Tuesday after the AI-driven biotech announced plans to reduce its workforce by approximately 20% as part of a ...